Cargando…
EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients
Mediastinal lymph node enlargement is common in the follow-up of patients with previously treated malignancies. The aim of this study is to assess the role of endobronchial ultrasound (EBUS) transbronchial needle aspiration (TBNA) for cyto-histological evaluation of positron emission tomography with...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651815/ https://www.ncbi.nlm.nih.gov/pubmed/29071277 http://dx.doi.org/10.1183/23120541.00009-2017 |
_version_ | 1783272954457489408 |
---|---|
author | Guarize, Juliana Casiraghi, Monica Donghi, Stefano Casadio, Chiara Diotti, Cristina Filippi, Niccolò Di Tonno, Clementina Midolo, Valeria Maisonneuve, Patrick Brambilla, Daniela Grana, Chiara Maria Petrella, Francesco Spaggiari, Lorenzo |
author_facet | Guarize, Juliana Casiraghi, Monica Donghi, Stefano Casadio, Chiara Diotti, Cristina Filippi, Niccolò Di Tonno, Clementina Midolo, Valeria Maisonneuve, Patrick Brambilla, Daniela Grana, Chiara Maria Petrella, Francesco Spaggiari, Lorenzo |
author_sort | Guarize, Juliana |
collection | PubMed |
description | Mediastinal lymph node enlargement is common in the follow-up of patients with previously treated malignancies. The aim of this study is to assess the role of endobronchial ultrasound (EBUS) transbronchial needle aspiration (TBNA) for cyto-histological evaluation of positron emission tomography with (18)fluorodeoxyglucose (PET) positive mediastinal and hilar lymph nodes developed in patients with previous malignancies. All EBUS-TBNA cases performed from January 2012 to May 2016 were retrospective reviewed. Results of EBUS-TBNA in patients with mediastinal and/or hilar lymphadenopathies were analysed. Non-malignant cytopathologies were confirmed with surgical procedures or clinical and radiological follow-up. Among 1780 patients, 176 were included in the analysis. 103 of these (58.5%) had a diagnosis of tumour recurrence whereas 73 (41.5%) had a different diagnosis: 63 (35.8%) had a non-neoplastic diagnosis and 8 patients (4.6%) had a different cell type malignancy. Samples were false-negative in 5 (2.8%) out of 176 patients. The overall sensitivity, specificity, negative predicted value and diagnostic accuracy were 95.7% (95% CI 90.2–98.6%), 100% (95% CI 94.0–100%), 92.3% (95% CI 83.2–96.7%) and 97.2% (95% CI 93.5–98.8%), respectively. EBUS-TBNA demonstrated a pathological diagnosis different from the previous tumour in a large percentage of patients, confirming its strategic role in the management of patients with previously treated malignancies. |
format | Online Article Text |
id | pubmed-5651815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-56518152017-10-25 EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients Guarize, Juliana Casiraghi, Monica Donghi, Stefano Casadio, Chiara Diotti, Cristina Filippi, Niccolò Di Tonno, Clementina Midolo, Valeria Maisonneuve, Patrick Brambilla, Daniela Grana, Chiara Maria Petrella, Francesco Spaggiari, Lorenzo ERJ Open Res Original Articles Mediastinal lymph node enlargement is common in the follow-up of patients with previously treated malignancies. The aim of this study is to assess the role of endobronchial ultrasound (EBUS) transbronchial needle aspiration (TBNA) for cyto-histological evaluation of positron emission tomography with (18)fluorodeoxyglucose (PET) positive mediastinal and hilar lymph nodes developed in patients with previous malignancies. All EBUS-TBNA cases performed from January 2012 to May 2016 were retrospective reviewed. Results of EBUS-TBNA in patients with mediastinal and/or hilar lymphadenopathies were analysed. Non-malignant cytopathologies were confirmed with surgical procedures or clinical and radiological follow-up. Among 1780 patients, 176 were included in the analysis. 103 of these (58.5%) had a diagnosis of tumour recurrence whereas 73 (41.5%) had a different diagnosis: 63 (35.8%) had a non-neoplastic diagnosis and 8 patients (4.6%) had a different cell type malignancy. Samples were false-negative in 5 (2.8%) out of 176 patients. The overall sensitivity, specificity, negative predicted value and diagnostic accuracy were 95.7% (95% CI 90.2–98.6%), 100% (95% CI 94.0–100%), 92.3% (95% CI 83.2–96.7%) and 97.2% (95% CI 93.5–98.8%), respectively. EBUS-TBNA demonstrated a pathological diagnosis different from the previous tumour in a large percentage of patients, confirming its strategic role in the management of patients with previously treated malignancies. European Respiratory Society 2017-10-23 /pmc/articles/PMC5651815/ /pubmed/29071277 http://dx.doi.org/10.1183/23120541.00009-2017 Text en Copyright ©ERS 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Original Articles Guarize, Juliana Casiraghi, Monica Donghi, Stefano Casadio, Chiara Diotti, Cristina Filippi, Niccolò Di Tonno, Clementina Midolo, Valeria Maisonneuve, Patrick Brambilla, Daniela Grana, Chiara Maria Petrella, Francesco Spaggiari, Lorenzo EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients |
title | EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients |
title_full | EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients |
title_fullStr | EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients |
title_full_unstemmed | EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients |
title_short | EBUS-TBNA in PET-positive lymphadenopathies in treated cancer patients |
title_sort | ebus-tbna in pet-positive lymphadenopathies in treated cancer patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651815/ https://www.ncbi.nlm.nih.gov/pubmed/29071277 http://dx.doi.org/10.1183/23120541.00009-2017 |
work_keys_str_mv | AT guarizejuliana ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT casiraghimonica ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT donghistefano ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT casadiochiara ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT diotticristina ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT filippiniccolo ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT ditonnoclementina ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT midolovaleria ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT maisonneuvepatrick ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT brambilladaniela ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT granachiaramaria ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT petrellafrancesco ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients AT spaggiarilorenzo ebustbnainpetpositivelymphadenopathiesintreatedcancerpatients |